Thrombophors® forte is a new direct—acting anticoagulant in the Promomed Group's anticoid portfolio

Promomed Group of Companies has received a registration certificate for a drug with an active substance calcium nadroparin. Nadroparin belongs to low molecular weight heparins. It has a high antithrombotic potential and helps reduce blood viscosity. Properties of the drug Thrombophors^® forte allows its use for the treatment of thrombosis and thromboembolism of various etiologies, including those that occur against the background of Covid-19.

Such serious and life-threatening conditions as deep vein thrombosis and pulmonary embolism (PE) are one of the most important problems of modern medicine. These diseases can occur when the internal walls of blood vessels are damaged, when blood circulation in the venous bed is disrupted, when the blood is capable of thrombosis, as well as when all these causes are combined. The main role in the formation of a blood clot is played by the activation of blood clotting processes, leading to the formation of a fibrin network in which individual erythrocytes and leukocytes get stuck — the so-called platelet-fibrin clot (platelet plug) is formed.

Thrombosis and thromboembolism have become a real challenge for the global health system, as they are a common complication in patients, including young people who do not have chronic diseases.

Promomed is actively working to expand the portfolio of drugs for complex therapy COVID-19. The company is focused on solving global medical problems and saving lives, so this is one of the priorities that we face. The introduction of Thrombophorse forte into clinical practice will expand the list of effective and safe drugs for the treatment of thrombosis and thromboembolism, which, among other things, are among the most dangerous consequences of coronavirus infection," she commented. Kira Zaslavskaya, Director of New Products, Promomed Group.

Nadroparin, the active ingredient of the drug, is a low molecular weight heparin, which has good bioavailability, low ability to bind to plasma proteins, optimal half-life, and therefore an anticoagulant effect. more predictable.

The drug Thrombophors^® forte is available in the form of a solution for subcutaneous administration. 1 ml of the solution contains 19,000 anti-Xa IU.

Promomed Group's anti-COVID portfolio, which already includes medicines aimed at treating COVID-19 of any severity, modern antibiotics and effective anticoagulants. It is now represented by products such as Areplivir.^®, Enoparin^® and others.